ライフサイエンスコーパス: clinical specimen

1 cter cloacae strain, M12X01451, from a human clinical specimen.

2 olitica or unspeciated Yersinia from a human clinical specimen.

3 y after initial isolation of bacteria from a clinical specimen.

4 drug targets and downstream substrates using clinical specimens.

5 ral use in reversing formaldehyde adducts in clinical specimens.

6 eatment, and detection of mixed infection in clinical specimens.

7 especially viral, are often scarce in human clinical specimens.

8 en CD117 or ZEB1 and DAB2IP is also found in clinical specimens.

9 viscosity and inactivated M. tuberculosis in clinical specimens.

10 molecular detection of meningococcal DNA in clinical specimens.

11 tection of human enterovirus D68 (EV-D68) in clinical specimens.

12 ing sufficient, highly pure genomic DNA from clinical specimens.

13 was developed to detect HIV-1 p24 antigen in clinical specimens.

14 validated in BRAF inhibitor-resistant NSCLC clinical specimens.

15 rapid method for detecting M. pneumoniae in clinical specimens.

16 ed in cellular models matched the pattern of clinical specimens.

17 able/nonviable isolates and culture-negative clinical specimens.

18 ns present at >2% of the viral population in clinical specimens.

19 on of intratumoral genetic heterogeneity for clinical specimens.

20 de rapid detection of respiratory viruses in clinical specimens.

21 , and F. tularensis is seldom recovered from clinical specimens.

22 ntire genome sequences from small amounts of clinical specimens.

23 erobic Gram-positive organisms isolated from clinical specimens.

24 ility of the assay target region from >2,100 clinical specimens.

25 robeads are employed for DNA extraction from clinical specimens.

26 4 x 10(-6) in cell lines and 2.6 x 10(-5) in clinical specimens.

27 ectrometry to identify pathogens directly in clinical specimens.

28 g the identification of yeasts isolated from clinical specimens.

29 within the 95% prediction intervals for the clinical specimens.

30 formalin-fixed and paraffin-embedded (FFPE) clinical specimens.

31 SIRT1 and also confirmed NRF2 activation in clinical specimens.

32 er bereziniae originally isolated from human clinical specimens.

33 he growth and identification of viruses from clinical specimens.

34 termined using 48 reference isolates and 254 clinical specimens.

35 e routine detection of viral nucleic acid in clinical specimens.

36 -regulated in prostate cancer cell lines and clinical specimens.

37 re needed when DNA-based methods are used on clinical specimens.

38 ctivation status in hormone-naive and CR-PCa clinical specimens.

39 as culture and directly straining smears of clinical specimens.

40 omoter in prostate cancer cell lines and the clinical specimens.

41 mens was performed and compared with that of clinical specimens.

42 nces occur in PCa cell lines, xenografts and clinical specimens.

43 ion of B. dermatitidis from culture and from clinical specimens.

44 y detecting a wide variety of organisms from clinical specimens.

45 , this organism has never been isolated from clinical specimens.

46 heir descendants were likewise identified in clinical specimens.

47 ll allow same-day detection of fungal DNA in clinical specimens.

48 subset of these ASRs for fungal isolates and clinical specimens.

49 protocol was applied to the analysis of 241 clinical specimens.

50 atum from culture isolates and directly from clinical specimens.

51 nin protein of influenza viruses directly in clinical specimens.

52 d assays have not been evaluated directly on clinical specimens.

53 atum from culture isolates and directly from clinical specimens.

54 per 10 000 hospital admissions had positive clinical specimens.

55 n a clinical laboratory and used directly on clinical specimens.

56 dult inpatients with S. aureus isolated from clinical specimens.

57 and small cell lung cancer (SCLC) lines and clinical specimens.

58 es with Snail level in cancer cell lines and clinical specimens.

59 R assay regarding 464 pathogens found in the clinical specimens.

60 ly with disease recurrence and metastasis in clinical specimens.

61 cordance between GATA2 and miR-194 levels in clinical specimens.

62 ly detect a variety of pathogens directly in clinical specimens.

63 further optimized for detecting PEDV RNA in clinical specimens.

64 so successfully applied to detecting PEDV in clinical specimens.

65 ed multiple organisms in 81 (5.86%) positive clinical specimens.

66 e obtained from ALK, ROS1 and RET FISH on 51 clinical specimens.

67 ependent manner both in RCC cell culture and clinical specimens.

68 apid detection of mycobacteria directly from clinical specimens.

69 y the panel in 1,382 (88.1%) of the positive clinical specimens.

70 not well understood due to limited access to clinical specimens.

71 Bipolaris spp.) was also identified in other clinical specimens.

72 ilable laboratory methods to identify VRE in clinical specimens.

73 ay expedite the identification of E. coli in clinical specimens.

74 Clinical specimens (9 cerebrospinal fluid [CSF], 13 gast

75 In clinical specimens, a genetic signature comprising four

76 In 90 colorectal cancer clinical specimens, a significant positive correlation w

77 All clinical specimens also contained two populations with n

78 Clinical specimen analysis revealed that reduced express

79 Evaluation of 21 clinical specimens and 115 clinical isolates demonstrate

80 rategy for the detection of acanthamoebae in clinical specimens and are likely to be more practical t

81 ly with Akt phosphorylation in breast cancer clinical specimens and cell lines.

82 lidate the selected ITS2 fragment, we tested clinical specimens and compared the species results obta

83 ent HAdV types were detected in three of the clinical specimens and confirmed by amplicon sequencing.

84 tform for analyzing protein glycosylation in clinical specimens and could complement the existing too

85 relevant to other contexts in which residual clinical specimens and data are used for research purpos

86 (kappa >/= 0.89) for the detection of CMV in clinical specimens and demonstrated increased sensitivit

87 A xenograft model of human GBM spheres from clinical specimens and direct clinical samples from pati

88 Clinical specimens and food samples were tested for botu

89 This observation was further validated with clinical specimens and functionally verified using demet

90 ecificity to detect and differentiate HSV in clinical specimens and identified 57 additional specimen

91 cytes, as well as in colon tumors from human clinical specimens and intestinal tumors from Apc(Min/+)

92 , and larval identification was attempted on clinical specimens and meat samples.

93 hroconis olivacea and Ochroconis ramosa from clinical specimens and Ochroconis icarus of an environme

94 etection and subtyping of influenza virus in clinical specimens and offers significant advantages ove

95 By studying lung adenocarcinoma clinical specimens and preclinical models, our computati

96 Accuracy was evaluated for 109 selected clinical specimens and revealed an average sensitivity a

97 tection of Neisseria gonorrhoeae only from a clinical specimen, and controls were individuals with a

98 MITF protein levels vary between and within clinical specimens, and amplifications and gain- and los

99 isolates, including 15 recovered from human clinical specimens, and found that they clustered with t

100 ontrols for direct patient care, handling of clinical specimens, and managing regulated medical waste

101 Analyses in human cells, clinical specimens, and mouse models demonstrated that R

102 ith EGFRvIII and phosphorylated Src(Y418) in clinical specimens, and such coexpression correlates wit

103 lecular methods with improved sensitivity on clinical specimens are being developed but are not yet r

104 A total of 343 clinical specimens as well as 29 external quality assess

105 Importantly, high nuclear TIAM1 in clinical specimens associates with increased CRC patient

106 e lung cancer cells, mouse models, and human clinical specimens before the onset of acquired drug res

107 Clinical specimens (blood, cerebrospinal fluid, and urin

108 ibraries prepared directly from a variety of clinical specimens (blood, urine, breast milk, respirato

109 Many studies of glycans rely on clinical specimens, but the low amount of sample availab

110 r versatility is well established for modern clinical specimens, but they have yet to be applied to a

111 al composition of challenging, heterogeneous clinical specimens by deep sequencing, culture-based str

112 c variations were identified in fresh frozen clinical specimens by Illumina RNA-sequencing, the STAR

113 In clinical specimens, CASC15 levels increased during melan

114 transport medium with 100 mul of a positive clinical specimen caused no loss of sensitivity by rRT-P

115 In clinical specimens, co-expression of various elements of

116 B card (BN), were evaluated using 200 frozen clinical specimens collected from January 2011 to June 2

117 wn titers and whole-blood, plasma, and urine clinical specimens collected from persons diagnosed with

118 clinical history, physical examination, and clinical specimen collection to determine if they had po

119 leic acid and 82.1% evaluated on unextracted clinical specimens compared to a validated real-time PCR

120 ty of the MTB-ISAD assay to detect MTB in 42 clinical specimens, confirming that the MTB-ISAD assay i

121 In clinical specimens, constant and variable quantification

122 Detection directly from 797 clinical specimens demonstrated specificities and sensit

123 inoma (NSCLC) cell lines, animal models, and clinical specimens demonstrates that suppression of SMAD

124 racterize a collection of low-passage-number clinical-specimen-derived N. gonorrhoeae isolates for Op

125 rapidly catalog the bacterial composition of clinical specimens directly from patients, without need

126 3B were coordinately induced in HPV-positive clinical specimens during cancer progression, likely thr

127 In clinical specimens, early-stage tumors that included >5%

128 In clinical specimens, elevated LAMB3 expression correlated

129 ouble minute chromosomes in more than 20% of clinical specimens examined, a frequency consistent with

130 roteomic data relies upon the quality of the clinical specimens examined.

131 rsity of drug sensitivities, with 70% of the clinical specimens exhibiting hypersensitivity to one or

132 For three clinical specimens, false negativity of the gold standar

133 From these samples, six clinical specimens (five blood, one synovial fluid) yiel

134 richment of CD133(hi)/ER(lo) cancer cells in clinical specimens following neoadjuvant endocrine thera

135 atory closed, the site handled close to 6000 clinical specimens for Ebola virus diagnosis and support

136 equence obtained directly from an unpassaged clinical specimen from a hospitalized infant.

137 me and conventional molecular approaches for clinical specimens from 1,051 patients submitted to the

138 Clinical specimens from 9 states during 2008-2010 were t

139 HIV-1 non-subtype B-infected clinical specimens from Cameroon were then used to optim

140 uated using 76 archived EHV isolates and 433 clinical specimens from cases of suspected EHV-1 infecti

141 variation of the MG192 gene among and within clinical specimens from different patients, MG192 sequen

142 Clinical specimens from dogs, cats, and horses were exam

143 ular characterization of viruses detected in clinical specimens from human cases revealed the presenc

144 esence and accessibility of this receptor in clinical specimens from index patients.

145 piratory viral pathogens or with 336 diverse clinical specimens from non-MERS-CoV cases; specimens fr

146 Data on Salmonella isolated from various clinical specimens from patients from across The Gambia

147 In clinical specimens from patients receiving riluzole, we

148 We applied RVS-HRM to clinical specimens from patients who developed oseltamiv

149 ith cardiovascular disease in foam cells and clinical specimens from patients with AS.

150 Archived clinical specimens from patients with confirmed DENV, JE

151 nt between FilmArray and qRT-PCR results for clinical specimens from patients with EVD were 85% (23/2

152 , supernatant of infected cell cultures, and clinical specimens from patients with EVD.

153 The expression of target genes in clinical specimens from patients with lung cancer was ex

154 l isolates suspicious for B. pseudomallei or clinical specimens from suspected melioidosis cases.

155 ions specific to bacteria derived from human clinical specimens from the calendar years 2012 through

156 Analysis of clinical specimens further showed that XPO5 phosphorylat

157 ect detection of Aspergillus nucleic acid in clinical specimens has the potential to improve the diag

158 n differential expression in a panel of PDAC clinical specimens, highlighting its potential as a biom

159 and isolation of the mold in the culture of clinical specimens; however, antigen detection has provi

160 lymerase chain reaction were used to analyze clinical specimens, human esophageal cell lines, and mou

161 We show that BV clinical specimens hydrolyze sialic acid from SIgA, but

162 ometry to measure over 2,000 compounds in 58 clinical specimens, identifying 35 metabolites which exh

163 with high titers, and for isolating VZV from clinical specimens.IMPORTANCE Varicella-zoster virus (VZ

164 filamentous fungi from yeasts directly from clinical specimens in less than 2.30 hours after DNA ext

165 Microbiology specimens are unique among clinical specimens in that optimal analysis may require

166 fication of >100 Lactobacillus isolates from clinical specimens in the context of presumed pathogenic

167 quencing (HTS) provides the means to analyze clinical specimens in unprecedented molecular detail.

168 RNA quality and provide excellent data from clinical specimens including formalin-fixed paraffin-emb

169 The DNA sample were collected from clinical specimens, including sputum and blood hemocultu

170 Furthermore, in clinical specimens, increased UBE3A levels correlated wi

171 Analysis of genomic data from clinical specimens indicated that related AR intragenic

172 ance, complete membrane proteome coverage of clinical specimen is usually hindered by the requirement

173 ntify parasites and determine the species in clinical specimens is established.

174 Loss of this chromatin remodeler in clinical specimens is significantly associated with an i

175 er chemotherapy, an observation confirmed in clinical specimens isolated longitudinally from a patien

176 s the sole pathogen isolated from 21% of the clinical specimens, its role in this epidemic, either al

177 Further, in clinical specimens, levels of Enpp1 were significantly e

178 Using clinical specimen material, we show reassortment between

179 In clinical specimens, miR-126 was strongly down-regulated

180 In clinical specimens (n = 1041), increased expression of E

181 When testing clinical specimens (n = 170), the MAP assay had a sensit

182 A total of 197 human clinical specimens obtained during cough-illness outbrea

183 er, phospho-Akt levels are increased in most clinical specimens obtained from EGFR-mutant non-small-c

184 Clinical specimens obtained through fine-needle aspirati

185 nd accurate detection of all IAV subtypes in clinical specimens of animal origin.

186 e findings, the presence of ICOS(+) cells in clinical specimens of breast cancer correlated with a po

187 In clinical specimens of breast cancer, reduced expression

188 in vitro along with tumor growth in vivo In clinical specimens of breast cancer, the absence of LMW-

189 he tumor suppressor genes DYRK1A and PTEN In clinical specimens of breast cancer, the expression of T

190 In clinical specimens of breast cancer, the presence of MDS

191 In clinical specimens of breast cancer, TRIB1 levels correl

192 In clinical specimens of breast cancer, we confirmed the pr

193 In clinical specimens of breast cancer, we established that

194 In clinical specimens of cancer, a strong correlation exist

195 In clinical specimens of cancer, less vascularized tumors e

196 In clinical specimens of cervical cancer, we confirmed that

197 Investigations in clinical specimens of chemoresistant EOC tissues confirm

198 In clinical specimens of colorectal cancer, miR-15a levels

199 In clinical specimens of endometrial adenocarcinoma, PME-1

200 In clinical specimens of glioblastoma multiforme, elevated

201 In clinical specimens of glioblastoma multiforme, we found

202 ke membrane protein DCBLD2 is upregulated in clinical specimens of glioblastomas and head and neck ca

203 In clinical specimens of glioma, HSP90 was upregulated in t

204 In clinical specimens of HCC, we observed S100P overexpress

205 In clinical specimens of head and neck cancer, we found tha

206 activation of mTOR is a widespread event in clinical specimens of HNSCCs invading locoregional lymph

207 In clinical specimens of human breast cancer, elevated leve

208 In clinical specimens of human glioblastoma, elevated level

209 lts from tumor and adjacent normal tissue in clinical specimens of human head and neck squamous carci

210 In clinical specimens of lung adenocarcinoma, low KLF10 exp

211 In clinical specimens of metastatic melanoma, we observed s

212 tial proteomics of fibroblasts isolated from clinical specimens of NFPAs with or without bone destruc

213 In clinical specimens of non-small cell lung cancer, we fou

214 ngly negative association with metastasis in clinical specimens of non-small cell lung cancer.

215 of miR-1258 and heparanase content in paired clinical specimens of normal mammary gland versus invasi

216 In clinical specimens of NSCLC with activating mutations of

217 High HOXA9 expression in clinical specimens of ovarian cancer was strongly associ

218 th NF-kappaB activation and disease stage in clinical specimens of ovarian cancer.

219 onocytes and with longer patient survival in clinical specimens of ovarian cancer.

220 Analysis of clinical specimens of PDAC showed that those with low SL

221 In clinical specimens of primary breast cancer or metastati

222 Galectin-4 expression in clinical specimens of prostate cancer correlated with po

223 Based on expression analysis performed on clinical specimens of salivary cancers, we identified in

224 ned if TGF-beta signaling is dysregulated in clinical specimens of sporadic mitral valve prolapse com

225 In clinical specimens of TNBC, elevated expression of TDO2

226 ited overlapping subcellular localization in clinical specimens of triple-negative breast carcinoma.

227 In clinical specimens of various human cancers, there was a

228 Analysis of primary clinical specimens of WDLPS, and of the closely related

229 ecently been used to identify pathogens from clinical specimens or after culture within about 6 h.

230 organisms can be seen upon Gram staining of clinical specimens or can be isolated as the predominant

231 activity was not observed when testing human clinical specimens or cultured viruses that were positiv

232 nusual or unexpected pathogens directly from clinical specimens, particularly when samples have been

233 Among the 159 patients with clinical specimens positive by both approaches, a total

234 only 11 of 24 (45.8%; 95% CI, 27.9 to 64.9) clinical specimens positive for adenovirus by real-time

235 evaluate the performance of this assay, 192 clinical specimens positive for MTBC by real-time PCR we

236 in a similar prospective study, in which 148 clinical specimens positive for MTBC DNA by real-time PC

237 In UCB clinical specimens, positive correlations in the express

238 Both in transgenic mice and in clinical specimens, proliferative cells did not usually

239 peline was challenged using HTS data from 20 clinical specimens representative of those most often co

240 -based pathogen identification directly from clinical specimens requires time-consuming interpretatio

241 tested on acid-fast-bacterium (AFB)-positive clinical specimens, resulting in sensitivity and specifi

242 An evaluation of clinical specimens revealed that FGFR4 was upregulated i

243 In clinical specimens, RGQ values were ~0.2 log(10) copies/

244 In clinical specimens, RNLS expression in the tumor correla

245 The results using clinical specimens show that the assay can detect infect

246 Analysis of clinical specimens showed elevated versican expression w

247 of the melanoma secretome and validation in clinical specimens showed that the heparin-binding facto

248 nally, we extended these findings to primary clinical specimens, showing that SKN is frequently overe

249 determine the stability of galactomannan in clinical specimens stored at -20 degrees C that were pos

250 Five hundred consecutive clinical specimens subjected to routine mycobacteria ide

251 We reviewed 1,150 results for clinical specimens submitted for DFA and culture and fou

252 proteins could be detected and quantified in clinical specimens such as colorectal and pancreatic tum

253 This small subset of patients and clinical specimens suggests that evolution of resistance

254 Retrospectively selected clinical specimens tested by a commercial reference labo

255 tection of galactomannan requires the use of clinical specimens that have been stored frozen.

256 In clinical specimens, the expression of GD3S correlates wi

257 In clinical specimens, the expression of SOX2 and SOX9 corr

258 For testing clinical specimens, the PSQ assay yielded a 98.4% sensit

259 In clinical specimens, there was an inverse relationship be

260 genotyping microbial pathogens directly from clinical specimens; this paves the way toward tests prov

261 known species and the only one reported from clinical specimens thus far, being recovered mainly from

262 When mycobacteria are recovered in clinical specimens, timely species-level identification

263 isolates from retail meat products and human clinical specimens to assess their similarity based on a

264 By using 292 clinical specimens to generate 2,238 paired individual a

265 nd whole-genome sequencing were performed on clinical specimens to identify species and assess strain

266 Further analyses of clinical specimens uncover a significant positive correl

267 Clinical specimens underwent routine processing with sub

268 ections by respiratory viruses isolated from clinical specimens using reconstituted human airway epit

269 We also found that increased CHOP mRNA in clinical specimens was a biomarker for poor outcomes in

270 The performance of the card on clinical specimens was evaluated with 1,050 blood sample

271 By using human clinical specimens, we also showed that miR-152 expressi

272 n plus a DNA microarray assay) directly from clinical specimens, we compared two commercial DNA extra

273 Extending these findings in clinical specimens, we documented an increase in TGF-bet

274 E)/Pten(-/-)/TPO-Cre tumor cells in vitro In clinical specimens, we found COL1A1 and LOX to be upregu

275 In clinical specimens, we found that CCN6 expression was in

276 In clinical specimens, we found that expression levels of K

277 nd, in order to facilitate identification of clinical specimens, we have studied a set of clinical an

278 In human clinical specimens, we observed an increase in megakaryo

279 els, cell line-based functional studies, and clinical specimens, we show that cyclin D1/CDK4 mediate

280 of the LSG-qPCR amplicons from reference and clinical specimens, we were able to differentiate four g

281 tained from M. tuberculosis culture-positive clinical specimens were also tested by Xpert at both rat

282 Of the 1648 cases for which clinical specimens were available, 50% were laboratory-c

283 s Trichoderma isolated from human and animal clinical specimens were characterized morphologically an

284 The multiplex assay results from 87 clinical specimens were compared to the individual RT-PC

285 ously typed HAdV field isolates and positive clinical specimens were correctly characterized by the t

286 olates representing 43 genera recovered from clinical specimens were evaluated.

287 Clinical specimens were obtained from a subset of these

288 A total of 130 clinical isolates and 129 clinical specimens were studied.

289 Nonviable isolates and culture-negative clinical specimens were tested for the lytA gene and, if

290 ommon anatomical sites of isolation in human clinical specimens were the respiratory tract (40%), fol

291 Primary clinical specimens were used to develop the assay and th

292 V genomes from different sample types (e.g., clinical specimens) were generated and sequenced using t

293 validated for testing clinical isolates and clinical specimens, which improves the turnaround time f

294 indirectly from multiple tests on peripheral clinical specimens, which may have imperfect and uncerta

295 routine next-generation sequencing (NGS) on clinical specimens will improve the capabilities of clin

296 Here we combine clinical specimens with biochemical approaches to invest

297 Excellent specificity was observed among clinical specimens with serologic or molecular markers f

298 d geographic clustering of HTNV strains from clinical specimens with the HTNV strains circulating in

299 iagnosing a panel of 13 bacterial species in clinical specimens within 2 h.

300 specific molecular approach for detection in clinical specimens, within 48 h of receipt, of both Myco